Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

Thomas Kaley(Memorial Sloan Kettering Cancer Center), Patrick Y. Wen(Memorial Sloan Kettering Cancer Center), David Schiff(Memorial Sloan Kettering Cancer Center), Keith L. Ligon(Memorial Sloan Kettering Cancer Center), Sam Haidar(Memorial Sloan Kettering Cancer Center), Sasan Karimi(Memorial Sloan Kettering Cancer Center), Andrew B. Lassman(Memorial Sloan Kettering Cancer Center), Craig Nolan(Memorial Sloan Kettering Cancer Center), Lisa M. DeAngelis(Memorial Sloan Kettering Cancer Center), Igor T. Gavrilovic(Memorial Sloan Kettering Cancer Center), Andrew D. Norden(Memorial Sloan Kettering Cancer Center), Jan Drappatz(Memorial Sloan Kettering Cancer Center), Eudocia Q. Lee(Memorial Sloan Kettering Cancer Center), Benjamin Purow(Memorial Sloan Kettering Cancer Center), Scott R. Plotkin(Memorial Sloan Kettering Cancer Center), Tracy T. Batchelor(Memorial Sloan Kettering Cancer Center), Lauren E. Abrey(Memorial Sloan Kettering Cancer Center), Antonio Omuro(Memorial Sloan Kettering Cancer Center)
Neuro-Oncology
August 6, 2014
Cited by 288Open Access
Full Text

Abstract

BACKGROUND: No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in meningiomas. METHODS: This was a prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with surgery and radiation-refractory recurrent World Health Organization (WHO) grades II-III meningioma. An exploratory cohort enrolled patients with WHO grade I meningioma, hemangiopericytoma, or hemangioblastoma. Sunitinib was administered at 50 mg/d for days 1-28 of every 42-day cycle. The primary endpoint was the rate of 6-month progression-free survival (PFS6), with secondary endpoints of radiographic response rate, safety, PFS, and overall survival. Exploratory objectives include analysis of tumoral molecular markers and MR perfusion imaging. RESULTS: Thirty-six patients with high-grade meningioma (30 atypical and 6 anaplastic) were enrolled. Patients were heavily pretreated (median number of 5 recurrences, range 2-10). PFS6 rate was 42%, meeting the primary endpoint. Median PFS was 5.2 months (95% CI: 2.8-8.3 mo), and median overall survival was 24.6 months (95% CI: 16.5-38.4 mo). Thirteen patients enrolled in the exploratory cohort. Overall toxicity included 1 grade 5 intratumoral hemorrhage, 2 grade 3 and 1 grade 4 CNS/intratumoral hemorrhages, 1 grade 3 and 1 grade 4 thrombotic microangiopathy, and 1 grade 3 gastrointestinal perforation. Expression of VEGFR2 predicted PFS of a median of 1.4 months in VEGFR2-negative patients versus 6.4 months in VEGFR2-positive patients (P = .005). CONCLUSION: Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.


Related Papers